BELGRADE, Mont. , Jan. 13, 2017 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE MKT:XTNT), a leader in the development, manufacturing and marketing of orthopedic products for domestic and international markets, today has announced that it has entered into an agreement with certain holders of

Record Fourth Quarter 2016 Revenue is estimated to be at least $24.5 million which represents 10.0% year on year growth Full Year 2016 Revenue is estimated to be at least $90.0 million which represents 4.1% year on year growth Fourth Quarter 2016 Adjusted EBITDA* is estimated to be at least $1.25

BELGRADE, Mont. , Nov. 23, 2016 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE MKT:XTNT), a leader in the development of regenerative medicine products and medical devices, today announced that the U.S. Food and Drug Administration ( FDA ) has cleared the Xsert Lumbar Expandable Interbody

BELGRADE, Mont. , Nov. 17, 2016 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE MKT:XTNT), a leader in the development, manufacturing and marketing of orthopedic products for domestic and international markets, announced today the closing of its rights offering (the "Offering") of units at a

BELGRADE, Mont. , Nov. 15, 2016 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE MKT:XTNT), a leader in the development, manufacturing and marketing of orthopedic products for domestic and international markets, announced today that the subscription period for its previously announced rights

BELGRADE, Mont. , Nov. 15, 2016 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE MKT:XTNT), a leader in the development of regenerative medicine products and medical devices, today announced that the U.S. Food and Drug Administration ( FDA ) has cleared the Irix-C cervical cage for use with

BELGRADE, Mont. , Nov. 14, 2016 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE MKT:XTNT), a leader in the development of regenerative medicine products and medical devices, today announced the first surgical cases of the Xspan Laminoplasty Fixation System.

BELGRADE, Mont. , Nov. 11, 2016 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE MKT:XTNT), a leader in the development, manufacturing and marketing of orthopedic products for domestic and international markets, reminds rights holders that the subscription period for its previously announced

BELGRADE, Mont. , Nov. 09, 2016 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE MKT:XTNT), a leader in the development, manufacturing and marketing of orthopedic products for domestic and international markets, announced today that it has adjusted the subscription price and related pricing

*See footnote about the use of pro forma financial information Third Quarter 2016 Highlights: Company revenue increased 10.5% to $23.1 million , as compared to pro forma revenue of $20.9 million in third quarter 2015 Gross profit increased to $16.0 million , as compared to pro forma third quarter